It has been suggested, based on rodent studies, that levodopa (l-dopa) induced dyskinesia
is associated with a disrupted blood–brain barrier (BBB). We have investigated BBB integrity …

Chronic levodopa treatment leads to the appearance of dyskinesia in the majority of
Parkinson's disease patients. Neurovascular dysregulation in putaminal and pallidal regions …

Research into the cause of dyskinesias arising from levodopa treatment has been vexingly
limited, partly due to the lack of an inexpensive and widely available animal model. Rodents …

The extent of nigrostriatal denervation is presumed to play a role in the genesis of levodopa‐
induced dyskinesia. Yet some parkinsonian patients who have been treated over a long …

Background Dopaminergic and serotonergic degenerations alter pharmacological
neurotransmission and structural markers in Parkinson's disease (PD). Alteration of diffusion …

Initially, treatment with the dopamine precursor levodopa provides substantial symptomatic
relief for patients with Parkinson's disease (PD). However, as the disease progresses, side …

Large increases in regional cerebral blood flow (rCBF) have been measured in patients with
Parkinson's disease (PD) following the administration of L-DOPA, but the underlying …

3, 4-Dihydroxyphenyl-l-alanine (l-DOPA)-induced dyskinesia is associated with molecular
and synaptic plasticity in the basal ganglia, but the occurrence of structural remodeling …

Dopamine denervation in Parkinson's disease and repeated Levodopa (L-DOPA)
administration that induces dyskinesias are associated with an enhancement of basal …

Post-mortem studies in human brain of patients with Parkinson's disease have greatly
contributed to our understanding of the disease. However, few human brain studies have …